Evidence map›Paper›PMID 41999499›Full record

ArticlePsychopharmacology2026

Home-cage pharmacology in marmosets: behavioral effects of scopolamine.

Haley E Harkins, Karen Christopher, Denis Matrov, Ivan D Ingram, Eric B Saglio, George R Dold, Yogita Chudasama

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Haley E Harkins *Section on Behavioral Neuroscience, National Institute of Mental Health, Bethesda, MD, 20892, USA.
Karen Christopher *Section on Behavioral Neuroscience, National Institute of Mental Health, Bethesda, MD, 20892, USA. karen.christopher@nih.gov.
Denis MatrovSection on Behavioral Neuroscience, National Institute of Mental Health, Bethesda, MD, 20892, USA.
Ivan D IngramSection on Behavioral Neuroscience, National Institute of Mental Health, Bethesda, MD, 20892, USA.
Eric B SaglioSection on Instrumentation, National Institute of Mental Health, Bethesda, MD, 20814, USA.
George R DoldSection on Instrumentation, National Institute of Mental Health, Bethesda, MD, 20814, USA.
Yogita ChudasamaSection on Behavioral Neuroscience, National Institute of Mental Health, Bethesda, MD, 20892, USA.

Funding

Neural Circuits Underlying the Control of Executive and Emotional BehaviorZIAMH002951 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI CHUDASAMA, YOGITA · 2016 to 2025
$17.5M
Intramural NIH HHS ZIA MH002951
6 · The paper itself

Abstract

RATIONALE AND

objectivesIn monkeys, the muscarinic cholinergic receptor antagonist scopolamine is known to broadly disrupt learned behaviors, though the precise nature of the cognitive deficits has been questioned. Experimentally observable deficits in memory can be ascribed to poor attentional focusing, human interference as well as age, sex, and dosing regimen. The potential stress associated with isolation can also play a role during behavioral testing, particularly in small nonhuman social primates like marmosets. In this study, we examine the effects of scopolamine in marmosets using a testing approach that plausibly reduces common stressors in marmosets by minimizing transport, handling, isolation and human interference.

methodsUsing a custom designed home-cage touchscreen-based testing system, we investigated the influence of scopolamine on the performance on a visual associative learning task. During self-paced, voluntary testing, monkeys learned to discriminate pairs of complex visual patterns through trial and error by touching the stimulus associated with reward. RESULTS AND

conclusionsEight marmosets (male and female) attained over 75% discrimination accuracy within three days of home-cage testing. The averaged data indicated no effect of acute or chronic scopolamine injections on learning rates. However, trial-level modeling of choice behavior revealed subtle age- and sex-specific deficits in performance accuracy that were not apparent in the aggregate measures. These findings highlight the value of home-cage testing combined with trial-level analysis for detecting nuanced behavioral effects of scopolamine.

Indexed as

Callithrix jacchusCholinergic receptorCognitionSingle trial analysisTouchscreenVisual discrimination

Identifiers

PMID41999499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.